(Q39309547)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Sreedhar Venkannagari

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Warren Fiskus

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Stacey L Hembruff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Rekha Rao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ramesh Balusu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Jacqueline E Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Karissa Peth

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Stephen C Peiper

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Kapil N Bhalla

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

24 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

433-444

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

Aurora kinases as targets for cancer therapy

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Aurora kinase inhibitors--rising stars in cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Roles of Aurora kinases in mitosis and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Aurora-A - a guardian of poles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Aurora kinase inhibitors: progress towards the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Regulation of mitosis via mitotic kinases: new opportunities for cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Vorinostat in solid and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Triple negative breast cancer: unmet medical needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2171-9

10.1007/S10549-012-2171-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825030%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference